SCHEMBL25190069

SCHEMBL25190069

CCN(CC)Cc1cc([N+](=O)[O-])cc(Cl)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 1/20 0.53
ALDH1A1 P00352 4/20 0.44
HTT P42858 4/20 0.44
POLB P06746 2/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
KDM4E B2RXH2 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
APEX1 P27695 1/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
MCL1 Q07820 1/20 0.43
HKDC1 Q2TB90 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 1/20 0.42
VCAM1 P19320 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25190096 0.89 GPR35 (0.46) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL30517202 0.89 HTT (0.50) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL25188801 0.88 GPR35 (0.50) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL9452233 0.85 GPR35 (0.61) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL25192576 0.83 GPR35 (0.48) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL25190113 0.83 GPR35 (0.48) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL25183606 0.82 GPR35 (0.47) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL25194959 0.82 HTT (0.64) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL25203588 0.82 HTT (0.44) GPR35ALDH1A1HTTPOLBKMT2A
SCHEMBL27979430 0.81 GPR35 (0.56) GPR35ALDH1A1HTTPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325547-A1 ANTI-SARS-COV-2 DRUG KAGOSHIMA UNIVERSITY (JP) 2025-10-23 US disclosed
EP-4431151-A1 ANTI-SARS-COV-2 DRUG Kagoshima University (JP) 2024-09-18 EP disclosed
CN-118302413-A Anti-SARS-CoV-2 medicine 国立大学法人鹿儿岛大学 2024-07-05 CN disclosed
WO-2023085392-A1 ANTI-SARS-COV-2 DRUG 国立大学法人鹿児島大学 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325547-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, AGTR2 GPR35 1908/4885ALDH1A1 2172/4885HTT 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.